Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340320 · ClinicalTrials.gov registry record · Phase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Corxel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT07340320: Recruiting Phase 2 study, sponsored by Corxel Pharmaceuticals.
NCT07340320 is a Phase 2 study that is actively recruiting participants, run by Corxel Pharmaceuticals. The registered enrollment target is 240 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07340320, a Phase 2 study, is actively recruiting participants, sponsored by Corxel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
Interventions
- OTHER Placebo
- DRUG CX11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-02-06 |
| Est. Completion | 2027-01-07 |
| Phase | Phase 2 |
What NCT07340320 shows while recruiting
NCT07340320 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07340320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07340320 about?
NCT07340320 is a clinical study titled "A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus". This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being don...
What is the current status of trial NCT07340320?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-02-06. Estimated completion is 2027-01-07.
What interventions are being tested in trial NCT07340320?
The interventions under investigation include: Placebo (OTHER), CX11 (DRUG).
Who is sponsoring clinical trial NCT07340320?
This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07340320's enrollment target sits among peer trials
240 239th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI